Becker's Healthcare September 10, 2024
Alexandra Murphy

In a phase 1/2 trial, researchers tested ATSN-101, a gene therapy for Leber congenital amaurosis 1, a rare genetic disorder that typically causes blindness in early childhood.

Fifteen patients with mutations in the GUCY2D gene were treated with increasing doses of ATSN-101. Overall, the subretinal therapy was well tolerated, with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
How Americans feel about weight-loss drugs, in 3 charts
Tariffs on China threaten could drive up drug costs, exacerbate shortages: 5 notes
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds

Share This Article